Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:SPRY

ARS Pharmaceuticals Q3 2026 Earnings Date & Estimates

ARS Pharmaceuticals logo
$3.00 -0.05 (-1.48%)
As of 12:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ARS Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ARS Pharmaceuticals in Q3 2026

ARS Pharmaceuticals is expected to post earnings of -$0.34 per share on revenue of $41.99 million. In the same quarter a year earlier ARS Pharmaceuticals reported -$0.52 per share on revenue of $32.50 million. ARS Pharmaceuticals last reported on August 13, 2026, posting -$0.63 per share and missing the -$0.4777 consensus estimate. ARS Pharmaceuticals has beaten the consensus EPS estimate in 1 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.34
Expected Revenue
$41.99 million
Prior-Year EPS
-$0.52
Prior-Year Revenue
$32.50 million
Expected Revenue Growth
+29.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.63 (Missed by -$0.1523)
Last Quarter Revenue
$33.66 million
EPS Beat Rate
1 of last 8 quarters

Prepare for the Q3 2026 Call

ARS Pharmaceuticals Q3 2026 Earnings FAQ

ARS Pharmaceuticals (NASDAQ:SPRY) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

ARS Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ARS Pharmaceuticals to post earnings of -$0.34 per share for Q3 2026.

The consensus revenue estimate for ARS Pharmaceuticals is $41.99 million for Q3 2026.

ARS Pharmaceuticals Earnings Headlines

ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling
November 3 at 2:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4961290-ars-pharmaceuticals-stock-lawsuits-cash-burn-priced-in-yet-stock-keeps-falling
ARS Pharmaceuticals, Inc. (SPRY) - What Are Researchers Saying About This Stock?
October 31 at 3:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31169525
Why Gerardo Del Real says wait before buying uranium stocks
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel
November 3 at 1:00 AM  |  Digest Publishing (Ad)
ARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on Thursday
October 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31167214
ARS Pharma to Report Third Quarter 2026 Financial Results
October 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390713/0/en/ars-pharma-to-report-third-quarter-2026-financial-results.html
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
October 5, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/10/05/10456997.htm
See More ARS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email.

About ARS Pharmaceuticals

ARS Pharmaceuticals (NASDAQ:SPRY) (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors. ARS Pharmaceuticals has also pursued additional regulatory approvals and expanded indications for neffy in other patient populations and markets.

ARS Pharmaceuticals was founded to develop intranasal therapies that can improve treatment delivery and patient access. The company is headquartered in San Mateo, California, and is led by Chief Executive Officer Richard Low. Its activities are primarily focused on advancing, obtaining regulatory approval for, and commercializing neffy and related intranasal drug-delivery technologies.

View ARS Pharmaceuticals Profile
Earnings Tools